OOIR: Observatory of International Research

Papers

(The TQCC of Experimental Hematology & Oncology is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience	200
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	168
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer	164
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives	142
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity	137
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies	111
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis	105
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	84
A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms	80
MENIN inhibitor-based therapy in acute leukemia: latest updates from the 2024 ASH annual meeting	79
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside	77
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics	75
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review	74
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling	73
Inhibition of EYA family tyrosine phosphatase activity reveals a therapeutic vulnerability and enhances Menin and DOT1L inhibitor efficacy in KMT2A-rearranged leukemia	70
Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy	68
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux	67
Correction: Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers	63
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response	62
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors	60
Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma	59
Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma	57
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy	54
All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone	54
HIV associated lymphoma: latest updates from 2023 ASH annual meeting	52

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways	51
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin	48
Correction: Breast cancer heterogeneity and its implication in personalized precision therapy	48
Enhanced cellular therapy: revolutionizing adoptive cellular therapy	46
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies	45
Role of m6A writers, erasers and readers in cancer	44
Breast cancer heterogeneity and its implication in personalized precision therapy	44
Three-dimensional chromatin landscapes in MLLr AML	43
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenström’s macroglobulinemia	42
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells	42
Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways	41
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma	41
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma	41
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting	41
Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study	40
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma	39
IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity	38
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation	38
TCR engineered T cells for solid tumor immunotherapy	37
The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination	37
Correction: Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	37
Myelodysplastic syndromes are multiclonal diseases derived from hematopoietic stem and progenitor cells	36
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia	34
Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11bhighCD27low memory-like NK cells	34
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs	33
circRanGAP1/miR-27b-3p/NRAS Axis may promote the progression of hepatocellular Carcinoma	33
IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response	32
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes	32
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances	32
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma	31
Hepatitis B surface antigen: carcinogenesis mechanisms and clinical implications in hepatocellular carcinoma	31
Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis	30
New exploration of KRASG12D inhibitors and the mechanisms of resistance	30
Immunotherapy in breast cancer: current landscape and emerging trends	30
Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study	29
Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review	29
A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation	29
The clinical impact of IKZF1 mutation in acute myeloid leukemia	29
Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy	28
Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors	28
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential	28
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model	27
Versatile function of NF-ĸB in inflammation and cancer	27
Antibody-drug conjugates in breast cancer: current evidence and future directions	27
A one-base therapeutic insertion in the HBG2 distal promoter reactivates γ-globin expression	26
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleuce	25
Recent advances and future perspectives in the therapeutics of prostate cancer	25
Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer	24
Crosstalk between O-GlcNAcylation and ubiquitination: a novel strategy for overcoming cancer therapeutic resistance	24
Immune-related gene index predicts metastasis for prostate cancer patients undergoing radical radiotherapy	24

Disparities in the incidence, mortality and disability-adjusted life years of 33 early-onset cancer groups globally, 2012–2021: a systematic analysis	24
KMT2A alterations in acute myeloid leukemia: a proposed genetic risk model and transplantation outcomes	24
Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma	24
Targeting secretory autophagy in solid cancers: mechanisms, immune regulation and clinical insights	24
The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity	23
FGL1-mediated lymph node metastasis in stage T1 non-small cell lung cancer: therapeutic targeting	23
CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications	23
Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma	23
A novel AML1-ETO/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia	23
Downregulation of pro-surfactant protein B contributes to the recurrence of early-stage non-small cell lung cancer by activating PGK1-mediated Akt signaling	23
Antitumor effect of a small-molecule inhibitor of KRASG12D in xenograft models of mucinous appendicular neoplasms	23
Validation of a microRNA profile in urine liquid biopsy with diagnostic and stratification value for bladder cancer classification, available through the open app BladdermiRaCan	22
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting	22
Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia	22
Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	22
Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study	22
CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy	22
Incidence, mortality, and risk factors of bladder, kidney, prostate and testicular cancers in China and comparisons with the United States, the United Kingdom, Japan, and the Republic of Korea: an up-	21
The roles of tissue resident macrophages in health and cancer	21
DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia	21
Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis	21
Immunotherapy in chronic lymphocytic leukemia: advances and challenges	21
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy	21
Sarcosine sensitizes lung adenocarcinoma to chemotherapy by dual activation of ferroptosis via PDK4/PDHA1 signaling and NMDAR-mediated iron export	20
The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment	20
Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	19
HOXA13 promotes gastric cancer progression partially via the FN1-mediated FAK/Src axis	19
Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting	19
Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients	19
Resolving intra-tumor heterogeneity and clonal evolution of core-binding factor acute myeloid leukemia patients with single-cell resolution	19
Bladder cancer subtypes exhibit limited plasticity across different microenvironments and in metastases	19
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA	19
Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancer	18
In-depth insight into tumor-infiltrating stromal cells linked to tertiary lymphoid structures and their prospective function in cancer immunotherapy	18
Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies	18
An ureido-substituted benzenesulfonamide carbonic anhydrase inhibitor exerts a potent antitumor effect in vitro and in vivo	18
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma	17
Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting	17
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies	17
Adefovir dipivoxil inhibits APL progression through degradation of the oncoprotein PML-RARA	17
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies	17
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities	17
Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults	17
Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance	17
Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates	17
Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications	17
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma	17